very good performance. second strong and We businesses. revenue morning, across delivered core Matt, our innovation initiatives share everyone. continued growth, investments We're many you contributing our pleased gains X.X% for Thank of quarter and commercial This to in team’s System. marks cash the strong solid or of quarter seventh straight power and execution the focused Danaher of Business with our a the core X% margin flow growth free combined expansion better and is to which testament we operating
also continue IPO to on track our the GE We planned anticipated relative and previously of our make communicated on and both transactions Biopharma business of our Dental expectations. remain acquisition to progress
we’re moods into excited XXXX half move the for that we ahead lie of and these second portfolio important the opportunities As about Danaher.
growth double-digit So and revenues our in and now revenues in growing Europe grew impact growth let’s single-digit in the Western We with mid quarter X%. translation of decreased X%, to Acquisitions results. foreign currency by of revenue by second with the while X.X% billion, increased X.X%. turn core Sales Geographically, markets to China. India range. saw markets high by U.S. across the grew XX% growth developed led both that approximately high single-digits growth growth $X.X
was was down XX.X%, Gross margin margin and profit quarter basis for the first operating year-over-year. XX XX.X%, points
XXX%. in basis growth and from double billion a foreign currency $X points U.S. ratio quarter XX a digit resulting the flow flow cash increased year-on-year. of dollar headwind margin operating We’ve year-on-year in conversion despite second stronger free income core cash to a However, generated meaningful net free of
single the fifth across digit at revenue X.X% or a increased This Life the core of growth. X.X% our quarter second core take look In let's with growth high in now revenue the portfolio. segment. So better is Sciences, results more detailed consecutive revenue reported quarter
basis This execution a performance DBS Reported increasing core was margin revenue to with core high by both growth up segment. Beckman the operating single basis counting XXX with flow as cytometry team's across XX.X% margin the in Sciences’ margins outstanding XXX was performance terrific driven and points double-digit a Life operating was growth particle points. profit characterization. result of and digit led
line by in was strength used led applications. in counting analyze to primarily The particle biopharmaceutical product Vi-CELL which viability cell is
with platform closed research customers on help the acquisition biopharma both to and efficiently. solution complex our addition Cytobank pairs analyze datasets Beckman cytometry software of a quickly In and that clinical flow more
rate. the ago. results business. continued our clinical applied SCIEX innovation We've pharmaceutical acquired XX SCIEX partially to investments mid-single of impact markets the at significant business at nearly a Good Core and a were across North American of end cadence at years made the grew improve tough in we the since digit by revenue offset comparison
several high helping analytical new highlighted handling spectrometry’s in a mass within workflow pursuit enables a first-of-its-kind products last applications including customers generation development be drug with solution very to team rich disease This The breakthrough throughput. used ASMS new Echo liquid their non-contact data the month in technology at MS treatments.
results due single-digit markets. At process businesses. year most industrial comparison tough This by offset growth strength our was revenue by driven major broad-based softer geographies to was was aerospace Pall mid and prior declined and digits which with markets. a across single partially core Pall, up in and Industrial and microelectronics strong end high end
which during iCELLis business we lines. Pall in demand using was broad-based product a by the biotech of across where Life highlight manufactured growth U.S. important FDA's gene saw Double-digit approval quarter bioreactor. Sciences with An Pall's our the led therapy is pediatric
children to to of Zolgensma is is SMA one number this disease. first or the the muscular atrophy spinal under death age genetic breakthrough of therapy treatment devastating the in and infants the cause gene SMA contribute Pall X. treat for to So for is proud
far. second IDT all across and be driven core so acquisition broad-based made delivered IDT product of major happier anniversary double-digit our with growth we by team quarter lines the marked one-year the geographies. progress of another quarter strength The has and the of revenue couldn't
XX.X% now costs. up reported attributable with currency revenue foreign with of the X.X% Diagnostics, down Moving to core basis margin to predominantly impact to margins headwinds dollar of U.S. This and tariff operating and the revenue is related reported growth points. related was X.X%. was decline core stronger XX Reported
At product way. its Beckman is business' in Diagnostics, of was Beckman high product core revenue immunoassay competitive growth launches China. mid-single-digit from driven particularly position enhancing automation line, by the and product recent number growth the benefiting By a key areas, trajectory. markets, led accelerating growth and Momentum
our in high-volume XXX see DxH to we We where our business are strong analyzer. ongoing encouraged particularly continue hematology improvements demand by for global new
digit high growth strength revenue with the across markets and achieved core single China. Radiometer developed
gas and blood performed competitive Our to wins gains. key both well AQT product share market with lines contributing
mid-single share market. up across histology driven results relative and Leica by digits. the Biosystems’ LBS Good were Advanced continued demand for to recently to core believe core we revenue Staining and take introduced was products
America. Finally, integrated progress at markets. in meaningful make core delivery funnel North particular DBS Cepheid embrace marketing growth than strong tools and XX% were of management momentum to transformative new up across like more revenue networks high processes on the is at growth enabled continued penetrating and Cepheid in success accounts team North results America has and
reflects down our XX decline investment rate lower declined points. Dental revenue on focused with basis the to was profit primarily basis impact margin exchange operating volume, declined Reported reported XXX new and down XX.X% points. segment, spend product core Turning foreign X%, This and movements reported of margins to core revenue and development. ongoing
declines low growth single-digit digit in businesses. consumables single were core Low partially in our our equipment specialty and business traditional offset by
more was offset China than in in growth Latin double-digit and Geographically continued by Western Europe America. softness
aligners clear Spark our highlighted As at of expansion in orthodontists orthodontics part of tradeshow business American into Association the our Ormco May.
a and cases. and aligner of comfortable made proprietary a TruGen aesthetic treating with Spark provides which highly exceptional is using complex flexibility capable material clarity
part a Following in of launch in group to initial expansion the leading are going early expect with and U.S. Australia build we traction our on previewing good targeted of orthodontists successful this Spark forward. a as
continue towards structure. year. have on Envista We establish new Dental senior progress the the a We’ve company's as second this in to announced remain company key leaders our We half and track IPO publicly make to of recently the trading business. operating name future separate intended its identified and of Envista good
segment. with core was basis increased X%. Environmental revenue revenue to up Reported margin and our Solutions XX XX basis and Reported XX.X% of margin points to Moving increased points X% operating expansion. Applied core
high-growth a digit increased In markets single-digit were Europe in Videojet underlying growth by revenue up at was core Western low year prior single low and single revenue solid Identification, demand end worldwide. with rate. Results high Product core versus a led comparison. market digits
and XXX and Esko the insight by were brings packaging we improvements Esko packaging performance hosted trends. together at event A to which sequential X-Rite across The our than product order forum In the provides User and workflow includes better World suppliers for unique Esko impactful business customers to Esko's ongoing guide Group showcase few weeks owners ago Esko Meeting in more Nashville. industry gather from in solutions innovation. brand the encouraged and to
mid-single markets strong turning by municipal execution markets with differentiation. saw Core commercial customer industrial double end digit developed product driven win was We and in and strength At its demand good new Finally, team growth solid up growth the the sustained digits. Quality. for revenue platform to the was and Trojan the Water in core rate revenue across China.
and American continue the and way strong single ChemTreat gas. markets digit in The delivered and food lead with growth. commercial beverage, facilities, high North results and core oil revenue Latin to American
the year America Lastly demand markets. performance Europe across at in a revenue low prior and benefited Good single-digit a Hach, rate core and Western versus double-digit comparison. industrial grew in from end North municipal
China as offset Hach's monitoring around offering. which was significant government in unique for demand water which partially by result was year meaningfully initiatives surface of This generated declines last a
it platforms one part portfolio Danaher. in of XXth the Through we and Hach's marks is strategic and of a of tenured as at how from billion evolved Water in tremendous grow Danaher of businesses and execution XXXX cornerstone and our foundation companies of a our $XXX M&A has Quality of XXXX $X.X combination example a the continuous build business operating what commitment year longest Hach today making a million platform. with DBS to improvement a now organic of
and platform byTrojan has the and time increased and over profit ChemTreat. treatment augment that XXXX water growth and basis than points by growth in adjacencies operating margins more acquisitions XX to During completed
with now the sustainable share invested value return and combination This drive excess platforms’ on and of capital inorganic initiatives build of in has organic XX%. consistent long-term helped gains
more headquarters this day at quality many to that join to we Loveland, our in Colorado. event upcoming at You'll will out able be and you in Hach's hope of the get September success story water investor for hear about us
Life first Science XXXX. for important transformational be our and The we of value Danaher feel So with to the that wrap half good and shareholders, anticipated up we year Envista expect platform. for remainder momentum about will GE to generated associates. the customers this the IPO incredibly we of moves Both maximize Biopharma in welcoming portfolio of to our
driven We the believe portfolio and Danaher commitment our value long-term the us for of build DBS combination XXXX strong our to through execution and uniquely performance team’s positions beyond. differentiated
assumes We which guidance We approximately are adjusted initiating between $X.XX year net core range net diluted expect $X.XX $X.XX adjusted be growth and full the XXXX of quarter in $X.XX. diluted EPS EPS third to of now to X.X%.
